Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
CYRUS R SAFINYA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · 2020 · $197,966 — ABSTRACT (PUBLICLY RELEASABLE) The current level of research activity involving gene therapy with either synthetic vectors (carriers) or engineered viruses is unprecedented. Liposomes are the most widely studied nonviral carriers worldwide for nucleic acid (NA) and drug delivery applications. Catio…
Yifan Cheng · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $292,301 — As a versatile structure determination technology, cryo-EM is an integrated part of the HARC Center. In the past funding cycle, the Cryo-EM Core has engaged in technology development of single-particle cryo-EM, and has made major contributions to the recent technological breakthroughs in single part…
S. Munir ALAM · DUKE UNIVERSITY · 2020 · $468,316 — Induction of broadly neutralizing antibodies (bnAbs) is a critical unmet goal of HIV vaccine development. BnAb DH511 is of high interest as a vaccine lead due to its very high breadth and the high in vivo protective potency of MPER bNAbs. Key challenges for inducing DH511-like bnAbs are: (a) the low…
Joel Kaar · UNIVERSITY OF COLORADO · 2020 · $178,987 — SUMMARY The formation of amyloid fibrils due to protein aggregation represents a central step in the pathogenesis of many age-related diseases for which there are no current cures. At the core of this step is the misfolding of one or more key proteins, which is converted from a natively folded or un…
Rebecca Long Heise · VIRGINIA COMMONWEALTH UNIVERSITY · 2020 · $217,379 — Acute Respiratory Distress Syndrome (ARDS) is diagnosed in 150,000 patients per year in the United States. These types of lung injury may be caused by severe infection, inhaling dangerous substances, or trauma. ARDS has a high impact on mortality with approximately half of all people diagnosed dying…
Lbachir BenMohamed · UNIVERSITY OF CALIFORNIA-IRVINE · 2020 · $210,375 — PROJECT SUMMARY/ABSTRACT A staggering number of individuals—over 3 billion worldwide—are currently infected with herpes simplex virus type 1 (HSV-1), which causes frequent, and often lifelong, bouts of recurrent corneal herpetic disease. This potentially blinding disease is a result of corneal re-i…
BABU L TEKWANI · SOUTHERN RESEARCH INSTITUTE · 2020 · $728,482 — PROJECT SUMMARY/ABSTRACT Development of dormant hypnozoites in the hepatic tissues, which may cause malaria relapse weeks to months after the initial infection, poses the major challenge for treatment & control of vivax malaria. 8- Aminoquinolines (8-AQs) are the only antimalarial drugs active agai…
NIGEL W BUNNETT · NEW YORK UNIVERSITY · 2020 · $282,990 — PROJECT SUMMARY This proposal examines the mechanisms by which G protein-coupled receptors (GPCRs) signal pain. Chronic pain is a hallmark of disease, a side effect of therapy, and a major cause of suffering. Although GPCRs mediate all aspects of nociception and are major therapeutic targets, the me…
WADIH ARAP · RBHS -CANCER INSTITUTE OF NEW JERSEY · 2020 · $642,804 — ABSTRACT Eight percent of patients diagnosed with prostate cancer progress to lethal metastatic disease. Development of resistance to androgen-deprivation therapy and eventually, to last line chemotherapeutics such as enzalutamide (ENZ), contribute to lethal, metastatic prostate cancer. While intere…
Forrest M Kievit · UNIVERSITY OF NEBRASKA LINCOLN · 2020 · $445,684 — PROJECT SUMMARY/ABSTRACT Traumatic brain injury (TBI) is the leading cause of disability and death in people under 45 with approximately 10 million new cases each year worldwide. The effects of TBI can be severe, including neurocognitive, physical, and psychosocial impairment. There remains a signi…
Clyde Jason Wright · UNIVERSITY OF COLORADO DENVER · 2020 · $490,696 — PROJECT SUMMARY Bronchopulmonary dysplasia (BPD) is the most common morbidity complicating preterm birth and predicts poor pulmonary and neurodevelopmental outcomes. Despite the well-documented association between inflammation and BPD, no safe and effective anti-inflammatory therapies to prevent BP…
Brian H. Johnston · SOMAGENICS, INC. · 2020 · $965,488 — Abstract Hepatitis D virus (HDV) infection is the most severe type of viral hepatitis, often causing accelerated liver damage that leads to end-stage liver disease. About 15–20 million individuals are infected by HDV worldwide. The absence of an effective treatment for acute forms of the disease and…
Suchismita Acharya · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2020 · $365,000 — Glaucoma is a neurodegenerative disease of the eye with an estimated prevalence of 80 million patients worldwide by 2020, at least 6 to 8 million becoming bilaterally blind. Elevated intraocular pressure (IOP) causing axonal degeneration of the optic nerve and progressive loss of retinal ganglion ce…
Zheng-Yi Chen · MASSACHUSETTS EYE AND EAR INFIRMARY · 2020 · $782,510 — Project Summary and Relevance Application of genome editing based therapy requires efficient delivery of editing agents into disease-relevant tissues and cells. Identification of novel delivery materials targeting somatic cells will greatly facilitate the advance of editing based therapy strategies …
Olga Gursky · BOSTON UNIVERSITY MEDICAL CAMPUS · 2020 · $427,652 — PROJECT SUMMARY / ABSTRACT The overall goal of this grant has been to understand in molecular details the action of apolipoproteins (apos) and lipoproteins in health and disease. The current focus is on human apoA-I, the major protein of plasma high-density lipoproteins (HDL, a.k.a. good cholesterol…
James Dahlman · GEORGIA INSTITUTE OF TECHNOLOGY · 2020 · $370,620 — Project Summary Scientists can create thousands of chemically distinct nanoparticles using a growing number of high throughput chemistries, but it is still difficult to test more than a few nanoparticles in vivo. The goal of this work is to substantially improve how lipid nanoparticles (LNPs) delive…
Robert F Place · MIRECULE, INC. · 2020 · $1,000,000 — Abstract: In this phase 2 SBIR application, miRecule proposes to develop a microRNA-based therapeutic mimic of miR- 30-5p (miRecule candidate MC-30) for the treatment of multi-drug resistant (MDR) cancers. Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common form of cancer. Greater t…
John Ramunas · REJUVENATION TECHNOLOGIES, INC. · 2020 · $272,403 — Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cir…
ZHENG-RONG LU · CASE WESTERN RESERVE UNIVERSITY · 2020 · $356,947 — The goal of this project is to develop smart dual-targeted lipid ECO/siRNA self-assembly nanoparticles to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat metastatic and drug-resistant triple negative breast cancer (TNBC). Metastasis and drug resistance are the main causes…
Bryce C Chackerian · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · 2020 · $513,123 — PROJECT SUMMARY Over 30% of the adult population of the United States has elevated levels of low-density lipoprotein cholesterol (LDL-C), a condition that is correlated with an increased risk of coronary heart disease and stroke. Lifestyle modifications and treatment with statins can be sufficient f…